V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 260018196 | 260009983 | 1.98 | 97.9 | Curative (C) | 2018-05-08 | 2018-05-27 | POMB | N | N | 260008455 | LANREOTIDE |
| 260018197 | 260019115 | 1.8 | null | Curative (C) | 2016-11-25 | 2016-11-28 | DHAP - R | 2 | N | 260008561 | IVE |
| 260018198 | 260009985 | 1.6 | 57.7 | Curative (C) | 2015-05-23 | 2015-06-15 | CYCLOPHOSPHAMIDE | null | N | 260008571 | CISPLATIN + RT |
| 260018199 | 260014735 | 1.79 | 88.8 | Palliative (P) | 2019-01-25 | 2019-01-30 | BLEOMYCIN + CISPLATIN + ETOPOSIDE + PACLITAXEL | 02 | null | 260008733 | CARBOPLATIN + ETOPOSIDE |
| 260018200 | 260009996 | 1.56 | 103 | Curative (C) | 2016-06-20 | 2016-06-20 | CISPLATIN + ETOPOSIDE + PACLITAXEL | 02 | N | 260008930 | VIP |
| 260018201 | 260010000 | 1.67 | 107.9 | Palliative (P) | 2017-05-21 | 2017-05-23 | Methotrexate High Dose (3g/m2) | 02 | N | 260008975 | CISPLATIN + RT |
| 260018202 | 260010004 | 1.83 | 81 | Palliative (P) | 2019-02-09 | 2019-03-08 | PMitCEBO | N | N | 260009010 | BEAM + ALEMTUZUMAB |
| 260018203 | 260010008 | 1.85 | 72 | null | 2016-09-21 | 2016-09-27 | BLEOMYCIN + VINCRISTINE | N | N | 260009056 | BLEOMYCIN + CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 260018204 | 260017072 | 1.62 | 56.6 | Disease modification (D) | 2017-03-06 | 2017-03-26 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | N | 260009099 | DOCETAXEL + TRASTUZUMAB |
| 260018205 | 260017074 | null | 91.1 | Curative (C) | 2019-03-17 | 2019-03-17 | BLEOMYCIN + VINCRISTINE | N | null | 260009422 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + PACLITAXEL |
| 260018206 | 260010020 | null | 71.7 | Curative (C) | 2017-08-08 | 2017-08-08 | POMB/ACE | N | N | 260009510 | ECX |
| 260018207 | 260018235 | 1.8 | null | Palliative (P) | null | 2016-01-29 | Panitumumab | N | null | 260009752 | POMB/ACE |
| 260018208 | 260010029 | 1.77 | null | Curative (C) | null | 2018-09-13 | CARBO + THIOTEPA + TOPOTECAN | N | N | 260009772 | BLEOMYCIN |
| 260018209 | 260014750 | 1.81 | 85.7 | Curative (C) | 2016-09-05 | 2016-09-11 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | 2 | N | 260009790 | CISPLATIN |
| 260018210 | 260014751 | null | 83.3 | Curative (C) | null | 2016-11-08 | VIP | 99 | null | 260009791 | ACE (GERM CELL) |
| 260018211 | 260010033 | 1.62 | 48.6 | Palliative (P) | 2017-02-18 | 2017-03-28 | DOCETAXEL + TRASTUZUMAB | N | N | 260009931 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 260018212 | 260010037 | 1.81 | 84.6 | null | 2019-10-07 | 2019-10-13 | Gemcitabine + Oxaliplatin | N | null | 260010054 | METHOTREXATE HIGH DOSE |
| 260018213 | 260010048 | 1.79 | 79.5 | Curative (C) | 2017-08-26 | 2017-09-13 | POMB | 02 | N | 260010341 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 260018214 | 260010050 | 1.78 | 76 | Disease modification (D) | 2016-08-10 | 2016-08-19 | STS Rhabdomyosarcoma RMS 2005 VA | N | N | 260010354 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260018215 | 260010054 | 1.77 | 72.4 | Curative (C) | 2018-01-07 | 2018-01-28 | VIP | N | N | 260010422 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260018216 | 260018821 | 1.66 | 83.9 | Palliative (P) | 2018-01-18 | 2018-01-19 | BLEOMYCIN + VINCRISTINE | 02 | N | 260010537 | GEMCITABINE + OXALIPLATIN |
| 260018217 | 260010058 | 1.66 | 76 | Adjuvant (A) | 2017-04-12 | 2017-04-22 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | N | 260010561 | TRASTUZUMAB |
| 260018218 | 260010064 | 0 | 95 | Disease modification (D) | 2016-08-19 | 2016-08-19 | CARBOPLATIN + ETOPOSIDE | 2 | N | 260010628 | PACLITAXEL |
| 260018219 | 260010065 | 1.75 | 83.9 | null | 2019-02-08 | 2019-03-23 | Obinutuzumab | N | N | 260010646 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 260018220 | 260010071 | null | null | Adjuvant (A) | 2016-05-13 | 2016-08-26 | BLEOMYCIN | N | null | 260010825 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + PACLITAXEL |
| 260018221 | 260010078 | 1.81 | 80.4 | Palliative (P) | 2014-08-09 | 2014-08-30 | Obinutuzumab | 2 | N | 260011239 | GEMCITABINE + OXALIPLATIN |
| 260018222 | 260014775 | 1.67 | null | Disease modification (D) | 2018-10-15 | 2019-06-12 | CVP | N | N | 260011267 | BLEOMYCIN + VINCRISTINE |
| 260018223 | 260010083 | null | 78 | Curative (C) | 2015-03-15 | 2015-03-21 | CARBO + THIOTEPA + TOPOTECAN | N | null | 260011419 | VINBLASTINE |
| 260018224 | 260017093 | 1.7 | 63.1 | Disease modification (D) | 2017-08-31 | 2017-09-05 | GEM-P | 02 | N | 260011453 | GDP R |
| 260018225 | 260010088 | 1.83 | 80.4 | Curative (C) | 2019-08-07 | 2019-08-07 | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 02 | N | 260011893 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260018226 | 260010090 | 1.56 | 66 | Palliative (P) | 2015-01-28 | 2015-01-28 | BLEOMYCIN + VINCRISTINE | 02 | N | 260011894 | BLEOMYCIN + VINCRISTINE |
| 260018227 | 260010096 | 1.72 | 87.1 | Curative (C) | 2016-04-23 | 2016-05-18 | ECX | N | N | 260012022 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 260018228 | 260010098 | 1.62 | 68.8 | Curative (C) | 2018-02-28 | 2018-02-28 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | N | N | 260012037 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 260018229 | 260010102 | null | 76.7 | Curative (C) | 2017-03-24 | 2017-04-03 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | 2 | N | 260012314 | POMB/ACE |
| 260018230 | 260010108 | 1.66 | 74 | Palliative (P) | 2018-08-13 | 2018-09-09 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE | N | N | 260012546 | VINBLASTINE |
| 260018231 | 260010113 | null | 76.4 | Curative (C) | 2017-12-28 | 2018-01-16 | ICE | 01 | Y | 260012721 | CARBOPLATIN + PACLITAXEL |
| 260018232 | 260014795 | null | 72.3 | Curative (C) | 2015-09-25 | 2015-10-11 | EP | N | N | 260014167 | IFOSFAMIDE + PACLITAXEL |
| 260018233 | 260014796 | 1.83 | 81.8 | Adjuvant (A) | 2013-08-06 | 2013-08-24 | PCV | N | N | 260014651 | CARBOPLATIN + ETOPOSIDE |
| 260018234 | 260010123 | 1.65 | null | Adjuvant (A) | 2019-09-11 | 2019-09-11 | Cisplatin + Radiotherapy | N | N | 260014883 | NIVOLUMAB |
| 260018235 | 260010134 | 1.62 | 111.7 | null | null | 2016-12-28 | Temozolomide 200mg/m2 | null | null | 260016240 | DOCETAXEL |
| 260018236 | 260017105 | 1.84 | 51.8 | Curative (C) | 2018-09-05 | 2018-09-29 | CYCLOPHOSPHAMIDE + VINORELBINE | N | N | 260016443 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260018237 | 260010140 | 1.7 | 85 | Palliative (P) | 2018-07-19 | 2018-07-19 | DHAP - R | 2 | N | 260016778 | ESHAP |
| 260018238 | 260018250 | 1.79 | 85.3 | Curative (C) | null | 2015-07-08 | Obinutuzumab | N | N | 260016927 | EP |
| 260018239 | 260017107 | 1.77 | 91.5 | Curative (C) | 2017-10-19 | 2017-10-19 | Cisplatin | 2 | N | 260017081 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260018240 | 260014808 | 1.91 | null | Disease modification (D) | 2019-08-08 | 2019-08-21 | CARBOPLATIN + ETOPOSIDE | N | N | 260017955 | BLEOMYCIN + VINBLASTINE |
| 260018241 | 260014811 | 1.73 | 72 | Palliative (P) | 2018-02-21 | 2018-04-22 | Cytarabine HD + Methotrexate HD | 2 | N | 260019247 | CYCLOPHOSPHAMIDE |
| 260018242 | 260010166 | 1.68 | 76 | Curative (C) | 2019-09-01 | 2019-09-13 | Carboplatin + Paclitaxel (3 weekly) | 2 | N | 260019465 | ALEMTUZUMAB + CYCLO + FLUDARABINE |
| 260018243 | 260014814 | 1.78 | 77.6 | Palliative (P) | null | 2016-08-28 | IFOSFAMIDE + PACLITAXEL | null | N | 260019645 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 260018244 | 260010172 | 0 | 85 | Palliative (P) | 2014-12-04 | 2014-12-18 | Carboplatin + Etoposide IV 3 day | N | N | 260019700 | PANITUMUMAB |
| 260018245 | 260017114 | 1.76 | 63.5 | Palliative (P) | 2013-12-03 | 2013-12-06 | GEMCARBO | N | null | 260020079 | R-EPOCH |